<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919109</url>
  </required_header>
  <id_info>
    <org_study_id>CDX-RSV-101P</org_study_id>
    <nct_id>NCT04919109</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children</brief_title>
  <official_title>Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codagenix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codagenix, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, randomized, double-blind, placebo-controlled clinical trial to&#xD;
      evaluate the safety of and immune response to CodaVax-RSV in 36 healthy children. They will&#xD;
      be vaccinated in summer to early autumn 2021 and followed through the 2021-22 RSV season. 18&#xD;
      children aged 2 to 5 years who are RSV-seropositive (have antibodies to RSV) and 18 children&#xD;
      aged 6 months to &lt; 2 years who are RSV-seronegative (do not have antibodies to RSV) will be&#xD;
      enrolled. Children will receive 2 doses of the vaccine or placebo (saline solution with no&#xD;
      active ingredient) as nose drops; doses will be 28 days apart.&#xD;
&#xD;
      A parent/guardian will record temperature and other conditions in a diary daily for 7 days&#xD;
      after each dose. The parent/guardian will be contacted by telephone on the day after Dose 1&#xD;
      for safety assessment and review of the diary data. Children will return to the clinic 3, 7,&#xD;
      14, and 28 days after each dose. The parent/guardian will then be contacted by telephone&#xD;
      monthly until 1 year after the second dose.&#xD;
&#xD;
      Study procedures include physical examinations, vital signs, and collections of blood and&#xD;
      nose/throat swab samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting expected adverse reactions</measure>
    <time_frame>Day 7</time_frame>
    <description>Reactogenicity Event Counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants reporting expected adverse reactions</measure>
    <time_frame>Day 36</time_frame>
    <description>Reactogenicity Event Counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participant reported adverse events</measure>
    <time_frame>Days 57</time_frame>
    <description>Adverse event counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Medically attended AEs (MAAEs), new-onset chronic illnesses (NCIs), and serious AEs (SAEs)</measure>
    <time_frame>Days 210</time_frame>
    <description>counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody</measure>
    <time_frame>Screening, Days 29 and 57</time_frame>
    <description>Neutralizing antibody level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as nose drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: CodaVax-RSV 10^6 PFU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Respiratory syncytial virus live attenuated vaccine against RSV administered as nose drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CodaVax-RSV</intervention_name>
    <description>live attenuated vaccine against RSV</description>
    <arm_group_label>Experimental: CodaVax-RSV 10^6 PFU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at the time of informed consent:&#xD;
&#xD;
               -  Part A: 2 to 5 years, inclusive&#xD;
&#xD;
               -  Part B: 6 months to &lt; 2 years&#xD;
&#xD;
          2. RSV Status at Screening:&#xD;
&#xD;
               -  Part A: RSV-seropositive&#xD;
&#xD;
               -  Part B: RSV-seronegative&#xD;
&#xD;
          3. Good general health status&#xD;
&#xD;
          4. Product of normal full-term pregnancy (36 to 42 weeks gestation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Household contact with any of the following groups of individuals for the period up to&#xD;
             14 days after each dose:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Infants &lt; 6 months of age&#xD;
&#xD;
               -  With hospitalization for asthma or other chronic respiratory disease in the past&#xD;
                  5 years&#xD;
&#xD;
               -  Immunocompromised individuals, which includes, but is not limited to, those with&#xD;
                  the following conditions:&#xD;
&#xD;
                    -  AIDS&#xD;
&#xD;
                    -  Receipt of chemotherapy within the past 6 months&#xD;
&#xD;
                    -  Current receipt of immunosuppressive agents&#xD;
&#xD;
                    -  Solid organ or bone marrow transplant&#xD;
&#xD;
          2. Enrolled in the same classroom at full-time day care with infants &lt; 6 months of age&#xD;
             for 14 days after each dose&#xD;
&#xD;
          3. Household contact of another child enrolled into the study&#xD;
&#xD;
          4. Inadequate venous access for repeated phlebotomy&#xD;
&#xD;
          5. Height and weight â‰¤ 5th percentile for age and sex (according to CDC growth charts for&#xD;
             children in Part A, according to World Health Organization Child Growth Standards for&#xD;
             children in Part B)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Codey Bell, MD</last_name>
    <phone>409-239-0988</phone>
    <email>drbell@tektonresearch.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV</keyword>
  <keyword>Live-attenuated vaccine</keyword>
  <keyword>respiratory infection</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Codon-deoptimized</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

